Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS

EGFR pathway is an important therapeutic target in human tumors, including metastatic colorectal cancer (mCRC). The advent of EGFR-targeted monoclonal antibodies panitumumab and cetuximab has generated promise for the treatment of mCRC and has largely improved patients’ progression-free survival (PF...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiang, Hu, Jing, Cheng, Lei, Ren, Wei, Yang, Mi, Liu, Baorui, Xie, Li, Qian, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734822/
https://www.ncbi.nlm.nih.gov/pubmed/26869800
http://dx.doi.org/10.2147/OTT.S86966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734822/
https://www.ncbi.nlm.nih.gov/pubmed/26869800
http://dx.doi.org/10.2147/OTT.S86966

Ejemplares similares